T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alcon
ALC
|
+$2.11B |
| 2 |
Linde
LIN
|
+$1.34B |
| 3 |
American International
AIG
|
+$1.34B |
| 4 |
Marvell Technology
MRVL
|
+$1.28B |
| 5 |
TSS
Total System Services, Inc.
TSS
|
+$1.24B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$2.27B |
| 2 |
Eli Lilly
LLY
|
+$1.64B |
| 3 |
NVIDIA
NVDA
|
+$1.59B |
| 4 |
RHT
Red Hat Inc
RHT
|
+$1.55B |
| 5 |
Booking.com
BKNG
|
+$1.12B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.88% |
| 2 | Healthcare | 16.96% |
| 3 | Financials | 13.79% |
| 4 | Consumer Discretionary | 13.57% |
| 5 | Industrials | 9.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
451
Lowe's Companies
LOW
$121B
| $215M | 0.03% |
2,127,145
-308,898
| -13% | -$32.6M |
|
452
Ameriprise Financial
AMP
$49.9B
| $214M | 0.03% |
1,476,905
-1,070,708
| -42% | -$155M |
|
|
P
453
Everpure Inc
P
$37B
| $212M | 0.03% |
13,909,034
+502,734
| +4% | +$9.82M |
|
454
Aramark
ARMK
$15.9B
| $210M | 0.03% |
8,056,870
-2,319,603
| -22% | -$54.3M |
|
455
VeriSign
VRSN
$25.6B
| $209M | 0.03% |
998,367
-8,766
| -0.9% | -$1.72M |
|
|
KL
456
DELISTED
Kirkland Lake Gold Ltd Ordinary
KL
| $207M | 0.03% |
4,831,849
+4,663,187
| +2,765% | +$162M |
|
457
Belden
BDC
$5.39B
| $207M | 0.03% |
3,471,860
-26,015
| -0.7% | -$1.49M |
|
458
Campbell Soup
CPB
$6.74B
| $204M | 0.03% |
5,079,326
+1,306,435
| +35% | +$51.3M |
|
459
Capitol Federal Financial
CFFN
$1.1B
| $203M | 0.03% |
14,718,123
+74,244
| +0.5% | +$1.01M |
|
|
FTV.PRA
460
DELISTED
Fortive Corporation 5.00% Mandatory Convertible Preferred Stock, Series A
FTV.PRA
| $202M | 0.03% |
197,335
+412
| +0.2% | +$427K |
|
461
HDFC Bank
HDB
$119B
| $202M | 0.03% |
6,213,944
-233,152
| -4% | -$7.03M |
|
462
Littelfuse
LFUS
$11.7B
| $202M | 0.03% |
1,141,364
-100,735
| -8% | -$18.3M |
|
463
Marathon Petroleum
MPC
$97.8B
| $202M | 0.03% |
3,613,039
-383,667
| -10% | -$21M |
|
464
Acadia Pharmaceuticals
ACAD
$5.07B
| $201M | 0.03% |
7,537,393
+179,737
| +2% | +$4.59M |
|
465
TJX Companies
TJX
$169B
| $201M | 0.03% |
3,806,894
-616,944
| -14% | -$32.8M |
|
|
NVRO
466
DELISTED
NEVRO CORP.
NVRO
| $200M | 0.03% |
3,078,635
+1,470,807
| +91% | +$91.6M |
|
467
Cardinal Health
CAH
$54.5B
| $198M | 0.03% |
4,205,388
+217,385
| +5% | +$10M |
|
468
Acadia Realty Trust
AKR
$2.84B
| $197M | 0.03% |
7,208,819
-148,381
| -2% | -$4.16M |
|
469
Canadian Natural Resources
CNQ
$98.1B
| $197M | 0.03% |
14,892,143
+1,361,465
| +10% | +$18.7M |
|
470
BioMarin Pharmaceuticals
BMRN
$13.6B
| $197M | 0.03% |
2,296,204
-185,337
| -7% | -$15.9M |
|
|
SAFM
471
DELISTED
Sanderson Farms Inc
SAFM
| $196M | 0.03% |
1,438,422
-338,811
| -19% | -$48.1M |
|
472
Cameco
CCJ
$43.1B
| $196M | 0.03% |
18,293,030
+213,313
| +1% | +$2.3M |
|
473
Brown & Brown
BRO
$23.8B
| $196M | 0.03% |
5,852,228
-24,673
| -0.4% | -$782K |
|
|
FRC
474
DELISTED
First Republic Bank
FRC
| $196M | 0.03% |
2,002,937
-1,448,855
| -42% | -$146M |
|
475
SLM Corp
SLM
$5.26B
| $192M | 0.03% |
19,720,737
-5,544,388
| -22% | -$54.9M |
|
Similar funds
T. Rowe Price Associates's Q2 2019 Portfolio in Review
As of Q2 2019, T. Rowe Price Associates held 2,600 positions worth $712B, up 4.7% from $680B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
T. Rowe Price Associates's Q2 2019 filing shows 72 new, 1,394 increased, 949 reduced and 59 closed positions. Its largest new stake was Alcon: 36,020,796 shares worth $2.23B. The largest sale was UnitedHealth, an estimated $2.27B.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 18% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q2 2019 buy was Alcon: 36,020,796 shares worth $2.23B.
- T. Rowe Price Associates added most to Linde in Q2 2019, an estimated $1.34B increase.
- T. Rowe Price Associates's biggest Q2 2019 reduction was UnitedHealth, cutting an estimated $2.27B.
- T. Rowe Price Associates fully exited Ultimate Software Group Inc in Q2 2019, selling an estimated $609M.
- T. Rowe Price Associates's ten largest holdings make up 21% of its $712B portfolio in Q2 2019.
- T. Rowe Price Associates opened 72 new positions and closed 59 in Q2 2019.
- T. Rowe Price Associates's portfolio value rose 4.7% quarter-over-quarter to $712B.
Based on T. Rowe Price Associates's 13F filing for Q2 2019, filed 15 Aug 2019.